Innocan Pharma: Potential for price explosion due to groundbreaking discovery in CBD research, even FDA approval in prospect!

Innocan Pharma: Potential for price explosion due to groundbreaking discovery in CBD research, even FDA approval in prospect!

According to a report from www.finanznachrichten.de,

Potential of InnoCan Pharma in CBD research

InnoCan Pharma (NASDAQ: INNOCAN) has announced a groundbreaking discovery in CBD research that points to potential FDA approval. The discovery came after extensive research and has potential implications for the market and industry.

The discovery suggests that data from studying LPT-CBD metabolism in selected animals could serve as a highly accurate reflection of human response to the same treatment. This could significantly strengthen Innocan Pharma's upcoming new drug application to the FDA. The liposomes in which the CBD molecules are packaged enable a continuous level of CBD in the body, which continuously develops the anti-inflammatory and pain-relieving effects of the CBD.

The clinical trials on dogs and animals were apparently successful, indicating that the method could also be promising for humans. The results suggest that InnoCan Pharma's sales could also rise sharply in the coming quarter.

The liposome-based CBD platform could have the potential to completely transform the CBD supplements market by offering more potent and long-lasting effects. The groundbreaking discovery alone has the potential to position the company in the industry and provide consumers with innovative CBD-related treatment options.